Literature DB >> 19146755

Validation of the line-probe assay for rapid detection of rifampicin-resistant Mycobacterium tuberculosis in Vietnam.

N S Shah1, N T N Lan, M N T Huyen, K Laserson, M F Iademarco, N Binkin, C Wells, J K Varma.   

Abstract

BACKGROUND: Delays in identifying multidrug-resistant tuberculosis (MDR-TB) contribute to higher TB morbidity and mortality, and ongoing transmission. The line-probe assay (LiPA) is a rapid, commercially available polymerase chain reaction based assay that detects most mutations in the rpoB gene for rifampicin (RMP) resistance. We validated and compared this assay with conventional drug susceptibility testing (DST).
METHODS: We re-cultured a random sample of stored isolates known to be either RMP-resistant or RMP-susceptible according to DST (proportion method). We performed a blinded comparison between LiPA and conventional DST. Genetic sequencing of the rpoB gene was performed on RMP-resistant isolates and discordant results.
RESULTS: We tested 79 RMP-resistant and 64 RMP-susceptible strains. Concordance of LiPA with DST was 94%. For detecting RMP resistance, LiPA sensitivity was 90% and specificity was 100%. Molecular analysis of possible false-negative isolates by LiPA revealed an absence of mutations in the rpoB gene. RMP resistance was a good proxy for MDR-TB, as 66 (93%) of 71 RMP-resistant isolates were also isoniazid-resistant.
CONCLUSION: The LiPA provided rapid results that were highly predictive of RMP resistance and MDR-TB. False-negatives occurred, but only among isolates with mutations in regions not assessed by LiPA. Performance and cost-effectiveness should be evaluated in patients during routine program conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19146755

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  4 in total

1.  Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study.

Authors:  S Mironova; E Pimkina; I Kontsevaya; V Nikolayevskyy; Y Balabanova; G Skenders; T Kummik; F Drobniewski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-25       Impact factor: 3.267

Review 2.  Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing.

Authors:  Ameeta S Kalokhe; Majid Shafiq; James C Lee; Susan M Ray; Yun F Wang; Beverly Metchock; Albert M Anderson; Minh Ly T Nguyen
Journal:  Am J Med Sci       Date:  2013-02       Impact factor: 2.378

3.  Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates.

Authors:  Muthuraj Muthaiah; Smita Sunil Shivekar; Vidya Raj Cuppusamy Kapalamurthy; Chitra Alagappan; Anbazhagi Sakkaravarthy; Usharani Brammachary
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-06-20

4.  Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa.

Authors:  Maunank Shah; Violet Chihota; Gerrit Coetzee; Gavin Churchyard; Susan E Dorman
Journal:  BMC Infect Dis       Date:  2013-07-29       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.